Clinical Trials Logo

Cognitive Dysfunction clinical trials

View clinical trials related to Cognitive Dysfunction.

Filter by:

NCT ID: NCT03511027 Withdrawn - Clinical trials for Cognitive Impairment

Medication Dispenser to Improve Care at Home for the Elderly

Start date: August 1, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the efficacy of the Karie Automated Medication delivery device in enhancing medication adherence among a group of elderly patients with mild to moderate cognitive decline.

NCT ID: NCT03507257 Recruiting - Alzheimer Disease Clinical Trials

Longitudinal Early-onset Alzheimer's Disease Study Protocol

LEADS
Start date: April 30, 2018
Phase:
Study type: Observational

The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EOnonAD) participants, and (3) cognitively normal (CN) control participants.

NCT ID: NCT03507192 Recruiting - Clinical trials for Mild Cognitive Impairment

Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.

Start date: September 25, 2017
Phase: N/A
Study type: Interventional

Muscle relaxation has been reported to be effective in alleviating anxiety and agitation symptoms in patients with dementia, but no studies have examined the effects of muscle relaxation therapy on cognitive function changes. Therefore, the purpose of this study is to compare and validate the improvement of cognitive function in patients with mild cognitive impairment and early alzheimer's dementia aged 50 to 85 years after performing muscle relaxation machine massage regularly.

NCT ID: NCT03504501 Terminated - Impaired Cognition Clinical Trials

Synaptic Plasticity and Cognitive Function in RASopathies

SynCoRAS
Start date: March 22, 2019
Phase: Phase 2
Study type: Interventional

The project is targeting cognitive impairment, one of the main health problems of patients with RAS pathway disorders. The aim of this study is to translate findings of animal studies to humans. This has been done by the applicants successfully for Lovastatin in Nf1. This result will be transferred to patients with Noonan Syndrome. lamotrigine is most likely a more effective and promising substance improving synaptic plasticity and consecutive cognitive function. It is expected that both substances are improving synaptic plasticity as well as alertness and changes in alertness may be a precondition for improvement of cognition.

NCT ID: NCT03503669 Completed - Clinical trials for Mild Cognitive Impairment

Reducing Risk for Alzheimer's Disease in High-Risk Women Through Yogic Meditation Training

Start date: May 1, 2018
Phase: N/A
Study type: Interventional

The purpose of this pilot study will be to test whether Kundalini yoga (KY) and Kirtan Kriya (KK) yogic meditation is superior to Memory Enhancement Training (MET) for improving cognitive functioning, health (including cardiovascular factors), and mood in women with high AD risk.

NCT ID: NCT03495037 Completed - Clinical trials for Subjective Cognitive Decline

Preventing Cognitive and Functional Decline Among Seniors at Risk

Start date: November 2, 2017
Phase: N/A
Study type: Interventional

This study evaluates the efficacy of Real-World Strategy Training (RWST) compared to a psycho-education workshop for improving everyday life performance in older adults with subjective cognitive decline (SCD). Participants will be randomly assigned to receive one of these approaches.

NCT ID: NCT03493178 Recruiting - Clinical trials for Mild Cognitive Impairment

Glutathione in Mild Cognitive Impairment

Start date: April 14, 2018
Phase: Early Phase 1
Study type: Interventional

Elderly humans have an increased risk of dementia which begins as mild defects in memory called mild cognitive impairment. Glutathione (GSH), a key endogenous antioxidant has been linked to cognition. This exploratory study will investigate mechanisms linked to GSH for cognitive impairment (and improvement) by studying humans with mild cognitive impairment who will be evaluated 12-weeks after receiving either N-acetylcysteine and glycine (GSH precursors), or receiving alanine, and a further 12-weeks after stopping these supplements.

NCT ID: NCT03487380 Terminated - Alzheimer Disease Clinical Trials

Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease

MiDCR
Start date: September 4, 2017
Phase: N/A
Study type: Interventional

The objective of the study is to highlight a modification of the composition of the intestinal microbiota associated with the diagnosis of Alzheimer's disease and its most unfavorable form, Rapid Cognitive Decline (DCR). This identification could lead to diagnostic strategies based on the analysis of the intestinal microbiome, and preventive and curative treatments, based on the modulation of intestinal microbiota

NCT ID: NCT03486938 Completed - Clinical trials for Mild Cognitive Impairment

Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease

HOPE4MCI
Start date: December 13, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective of the study is to evaluate the efficacy of AGB101 on slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with mild cognitive impairment due to Alzheimer's Disease (MCI due to AD) also known as prodromal AD. Participants will be randomized to receive placebo or AGB101 (220 mg), once daily for 78 weeks. Secondary objectives are to assess the effect of AGB101 compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE) and Functional Activities Questionnaire (FAQ).

NCT ID: NCT03486782 Completed - Stroke Clinical Trials

Dual Site-dual Channel Non-invasive Brain Stimulation for Language and Cognitive Function in Stroke Patients

Start date: May 29, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the effect of dual site-dual channel non-invasive brain stimulation for recovery of language and cognitive function in post stroke patients. Simultaneous dual site-dual channel stimulation was applied by using two sets of transcranial direct current stimulation devices. All subjects will go through four conditions of transcranial direct current stimulation with for 30 minutes. Four conditions are 1) Dual stimulation: i) anodal stimulation on ipsilesional inferior frontal cortex, ii) anodal stimulation on ipsilesional dorsolateral prefrontal cortex. 2) Single stimulation 1: anodal stimulation on ipsilesional inferior frontal cortex and cathodal stimulation on contralesional inferior frontal cortex; 3) Single stimulation 2: anodal stimulation on ipsilesional inferior frontal cortex and cathodal stimulation on contralesional supraorbital area.